INTERVENTION 1:	Intervention	0
Ixabepilone/Trastuzumab/Carboplatin	Intervention	1
Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate	Intervention	2
ixabepilone	CHEBI:63605	27-38
carboplatin	CHEBI:31355	56-67
surgery	OAE:0000067	81-88
adjuvant	CHEBI:60809	3-11
adjuvant	CHEBI:60809	135-143
patient	HADO:0000008,OAE:0001817	158-165
Ixabepilone: Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)	Intervention	3
ixabepilone	CHEBI:63605	0-11
ixabepilone	CHEBI:63605	13-24
day	UO:0000033	61-64
day	UO:0000033	110-113
length	PATO:0000122	118-124
Trastuzumab: Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52	Intervention	4
day	UO:0000033	84-87
day	UO:0000033	164-167
day	UO:0000033	209-212
day	UO:0000033	380-383
minute	UO:0000031	43-49
minute	UO:0000031	101-107
minute	UO:0000031	240-246
length	PATO:0000122	217-223
week	UO:0000034	336-340
week	UO:0000034	394-398
week	UO:0000034	406-410
Carboplatin: Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)	Intervention	5
carboplatin	CHEBI:31355	0-11
carboplatin	CHEBI:31355	13-24
day	UO:0000033	66-69
day	UO:0000033	115-118
length	PATO:0000122	123-129
Inclusion Criteria:	Eligibility	0
Female and male patients 18 years of age.	Eligibility	1
female	PATO:0000383	0-6
male	CHEBI:30780,PATO:0000384	2-6
male	CHEBI:30780,PATO:0000384	11-15
age	PATO:0000011	37-40
Histologically confirmed adenocarcinoma of the breast.	Eligibility	2
adenocarcinoma	DOID:299	25-39
breast	UBERON:0000310	47-53
Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-T3, N1-N2, M0). (T1N0M0 lesions are excluded.)	Eligibility	3
disease	DOID:4,OGMS:0000031	17-24
breast	UBERON:0000310	39-45
breast	UBERON:0000310	303-309
physical examination	OAE:0004232	60-80
diameter	PATO:0001334	192-200
size	PATO:0000117	327-331
excluded	HP:0040285	381-389
Patients who have no clearly defined palpable breast mass or axillary lymph nodes but are radiographically measurable are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. In these patients, radiographic tumor measurements need to be repeated after 3 cycles and prior to surgery.	Eligibility	4
breast mass	HP:0032408	46-57
lymph	UBERON:0002391	70-75
breast disease	DOID:3463	166-180
breast	UBERON:0000310	46-52
breast	UBERON:0000310	166-172
breast	UBERON:0000310	207-213
surgery	OAE:0000067	325-332
Positive HER2 status (overexpression and/or amplification of HER2 in the primary tumor) as defined by: IHC 3+ or fluorescence in situ hybridization (FISH) positive (ratio >2.2) testing. Documentation of the HER2 results must be available at the time of study enrollment.	Eligibility	5
ratio	UO:0000190	165-170
time	PATO:0000165	245-249
An ECOG (Eastern Cooperative Oncology Group) performance score of 2	Eligibility	6
group	CHEBI:24433	38-43
Normal bone marrow function as defined by:	Eligibility	7
bone marrow	UBERON:0002371	7-18
function	BAO:0003117,BFO:0000034	19-27
absolute neutrophil count (ANC) >1,500/µL;	Eligibility	8
platelets >100,000/µL;	Eligibility	9
hemoglobin >10 g/dL.	Eligibility	10
hemoglobin	CHEBI:35143	0-10
Normal hepatic and renal function.	Eligibility	11
function	BAO:0003117,BFO:0000034	25-33
Left ventricular ejection fraction (LVEF) within the institutional limits of normal, whichever is lower, as measured by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO).	Eligibility	12
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
Life expectancy > 12 weeks.	Eligibility	13
Estrogen and progesterone (or estrogen alone) receptor status in the primary tumor known or pending at the time of study enrollment.	Eligibility	14
estrogen	CHEBI:50114,BAO:0000760	0-8
estrogen	CHEBI:50114,BAO:0000760	30-38
progesterone	CHEBI:17026	13-25
receptor	BAO:0000281	46-54
time	PATO:0000165	107-111
For women of childbearing potential, negative serum pregnancy test within 7 days prior to starting treatment.	Eligibility	15
For women of childbearing potential, agreement to use a method of contraception that is acceptable to their physician from time of first signing the informed consent until at least 3 months after the last dose of study drug. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately. Patient agreement to discontinue breast-feeding, if applicable, during study treatment. Men enrolled in the study must also agree to use a method of contraception that is acceptable to their physician during their study participation.	Eligibility	16
time	PATO:0000165	123-127
drug	CHEBI:23888	219-223
patient	HADO:0000008,OAE:0001817	377-384
For patients with previous invasive cancers (including breast cancer) treated with curative intent, completion of chemotherapy or radiation therapy more than 5 years prior to enrollment for this study and no evidence of recurrent disease. Patients may be receiving anti-estrogen hormonal therapy prescribed for previous invasive breast cancer as long as the diagnosis of invasive cancer was made more than 5 years prior to study enrollment. Patients may be using anti-estrogen hormonal therapy at the time of current diagnosis but must discontinue this therapy before beginning study treatment.	Eligibility	17
breast cancer	DOID:1612	55-68
breast cancer	DOID:1612	329-342
recurrent	HP:0031796	220-229
disease	DOID:4,OGMS:0000031	230-237
anti-estrogen	CHEBI:50751	265-278
anti-estrogen	CHEBI:50751	463-476
cancer	DOID:162	36-42
cancer	DOID:162	62-68
cancer	DOID:162	336-342
cancer	DOID:162	380-386
time	PATO:0000165	501-505
For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound.	Eligibility	18
lymph	UBERON:0002391	44-49
Ability to understand and willingness to sign a written informed consent document.	Eligibility	19
document	IAO:0000310	73-81
Exclusion Criteria:	Eligibility	20
Previous treatment for this breast cancer.	Eligibility	21
breast cancer	DOID:1612	28-41
Evidence of metastatic disease.	Eligibility	22
disease	DOID:4,OGMS:0000031	23-30
Prior radiation that included 30% of major bone marrow-containing areas.	Eligibility	23
Women who are pregnant or breastfeeding.	Eligibility	24
Neuropathy (motor or sensory) grade 1 at study entry.	Eligibility	25
neuropathy	DOID:870	0-10
History of significant cardiac disease or cardiac risk factors or the following:	Eligibility	26
history	BFO:0000182	0-7
disease	DOID:4,OGMS:0000031	31-38
uncontrolled arrhythmias	Eligibility	27
poorly controlled hypertension (e.g., systolic blood pressure [BP]> 150 mmHg or diastolic BP >100 mmHg) in spite of optimal medical management	Eligibility	28
hypertension	HP:0000822,DOID:10763	18-30
systolic blood pressure	CMO:0000004	38-61
angina pectoris requiring antianginal medication or unstable angina within the previous 6 months	Eligibility	29
angina pectoris	HP:0001681	0-15
history of documented congestive heart failure (CHF)	Eligibility	30
history	BFO:0000182	0-7
congestive heart failure	HP:0001635,DOID:6000	22-46
any documented myocardial infarction within the previous 6 months	Eligibility	31
myocardial infarction	HP:0001658,DOID:5844	15-36
clinically significant valvular heart disease	Eligibility	32
heart disease	DOID:114	32-45
current use of medications (e.g., digitalis, beta-blockers, calcium channel-blockers) that alter cardiac conduction, if these medications are administered for the management of cardiac arrhythmia, angina, or CHF. If these medications are administered for other reasons (e.g., hypertension), the patient may be eligible.	Eligibility	33
calcium	CHEBI:22984,BAO:0000874	60-67
cardiac conduction	GO:0061337	97-115
arrhythmia	HP:0011675	185-195
hypertension	HP:0000822,DOID:10763	276-288
patient	HADO:0000008,OAE:0001817	295-302
patients with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG unless ECHO or MUGA scan within the last 3 months demonstrates that the LVEF is  institutional lower limit of normal.	Eligibility	34
cardiomegaly	HP:0001640	14-26
chest	UBERON:0001443	30-35
ventricular hypertrophy	HP:0001714	45-68
Symptomatic intrinsic lung disease.	Eligibility	35
lung disease	DOID:850	22-34
Active malignancy, other than superficial basal cell carcinoma, superficial squamous (skin) cell carcinoma, carcinoma in situ, or non-invasive breast cancer, within the past 5 years.	Eligibility	36
active	PATO:0002354	0-6
superficial basal cell carcinoma	DOID:4300	30-62
carcinoma	HP:0030731,DOID:305	53-62
carcinoma	HP:0030731,DOID:305	97-106
carcinoma	HP:0030731,DOID:305	108-117
breast cancer	DOID:1612	143-156
Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection >grade 2.	Eligibility	37
active	PATO:0002354	76-82
Mental condition or psychiatric disorder rendering the subject unable to understand the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.	Eligibility	38
condition	PDRO:0000129	7-16
disorder	OGMS:0000045	32-40
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving a reasonable suspicion of a disease or condition that contraindicates the use of a study agent or that may affect the interpretation of the results or renders the subjects at high risk from treatment complications.	Eligibility	39
disease	DOID:4,OGMS:0000031	10-17
disease	DOID:4,OGMS:0000031	138-145
physical examination	OAE:0004232	42-62
laboratory finding	OGMS:0000018	84-102
condition	PDRO:0000129	149-158
Chronic use of CYP3A4 inhibitors and use of the following strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole. Use of these agents must be discontinued at least 72 hours prior to initiation of study treatment.	Eligibility	40
chronic	HP:0011010	0-7
ketoconazole	CHEBI:47519,BAO:0000796	84-96
itraconazole	CHEBI:6076	98-110
clarithromycin	CHEBI:3732	112-126
atazanavir	CHEBI:37924	128-138
nefazodone	CHEBI:7494	140-150
saquinavir	CHEBI:63621	152-162
telithromycin	CHEBI:29688	164-177
ritonavir	CHEBI:45409	179-188
amprenavir	CHEBI:40050	190-200
indinavir	CHEBI:44032	202-211
nelfinavir	CHEBI:7496	213-223
delavirdine	CHEBI:119573	225-236
voriconazole	CHEBI:10023	242-254
Received chemotherapy for any indication within the 5 years preceding study enrollment.	Eligibility	41
Prior treatment with trastuzumab or any other anti-HER2 agent for any indication.	Eligibility	42
Concurrent treatment with any other anti-cancer therapy.	Eligibility	43
Concurrent radiation therapy during neoadjuvant study treatment.	Eligibility	44
Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to study enrollment.	Eligibility	45
Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention of breast cancer. These agents must be discontinued prior to study enrollment.	Eligibility	46
raloxifene	CHEBI:8772	48-58
tamoxifen	CHEBI:41774	60-69
estrogen	CHEBI:50114,BAO:0000760	90-98
receptor	BAO:0000281	99-107
osteoporosis	HP:0000939,DOID:11476	139-151
breast cancer	DOID:1612	169-182
Participation within the previous 30 days in a study with an experimental drug.	Eligibility	47
drug	CHEBI:23888	74-78
Known or suspected allergy to Cremophor EL (polyoxyethylated castor oil), a drug formulated in Cremophor EL such as paclitaxel, or any other agent given in the course of this trial.	Eligibility	48
allergy	HP:0012393	19-26
castor oil	CHEBI:140618	61-71
drug	CHEBI:23888	76-80
paclitaxel	CHEBI:45863	116-126
Inability or unwillingness to comply with study procedures including those for follow-up.	Eligibility	49
Outcome Measurement:	Results	0
Pathologic Complete Response (pCR)	Results	1
Proportion of patients who do not exhibit residual invasive breast cancer in breast or axillary lymph nodes at time of surgery	Results	2
breast cancer	DOID:1612	60-73
breast	UBERON:0000310	60-66
breast	UBERON:0000310	77-83
lymph	UBERON:0002391	96-101
time	PATO:0000165	111-115
surgery	OAE:0000067	119-126
Time frame: average18 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Ixabepilone/Trastuzumab/Carboplatin	Results	5
Arm/Group Description: Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate	Results	6
ixabepilone	CHEBI:63605	50-61
carboplatin	CHEBI:31355	79-90
surgery	OAE:0000067	104-111
adjuvant	CHEBI:60809	26-34
adjuvant	CHEBI:60809	158-166
patient	HADO:0000008,OAE:0001817	181-188
Ixabepilone: Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)	Results	7
ixabepilone	CHEBI:63605	0-11
ixabepilone	CHEBI:63605	13-24
day	UO:0000033	61-64
day	UO:0000033	110-113
length	PATO:0000122	118-124
Trastuzumab: Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52	Results	8
day	UO:0000033	84-87
day	UO:0000033	164-167
day	UO:0000033	209-212
day	UO:0000033	380-383
minute	UO:0000031	43-49
minute	UO:0000031	101-107
minute	UO:0000031	240-246
length	PATO:0000122	217-223
week	UO:0000034	336-340
week	UO:0000034	394-398
week	UO:0000034	406-410
Carboplatin: Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)	Results	9
carboplatin	CHEBI:31355	0-11
carboplatin	CHEBI:31355	13-24
day	UO:0000033	66-69
day	UO:0000033	115-118
length	PATO:0000122	123-129
Overall Number of Participants Analyzed: 52	Results	10
Measure Type: Number	Results	11
Unit of Measure: participants  27	Results	12
Adverse Events 1:	Adverse Events	0
Total: 17/58 (29.31%)	Adverse Events	1
Febrile Neutropenia 4/58 (6.90%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Constipation 1/58 (1.72%)	Adverse Events	3
constipation	HP:0002019,DOID:2089	0-12
Diarrhea 1/58 (1.72%)	Adverse Events	4
diarrhea	HP:0002014,DOID:13250	0-8
Duodenal ulcer 1/58 (1.72%)	Adverse Events	5
duodenal ulcer	HP:0002588,DOID:1724	0-14
Fever 1/58 (1.72%)	Adverse Events	6
fever	HP:0001945	0-5
Non-cardiac chest pain 1/58 (1.72%)	Adverse Events	7
chest pain	HP:0100749	12-22
Cholecystitis 1/58 (1.72%)	Adverse Events	8
cholecystitis	HP:0001082,DOID:1949	0-13
Infections and infestations - Other, MRSA 2/58 (3.45%)	Adverse Events	9
Bronchial infection 1/58 (1.72%)	Adverse Events	10
Infections and infestations - Other, pneumonia 1/58 (1.72%)	Adverse Events	11
pneumonia	HP:0002090,DOID:552	37-46
